Irinotecan sucrosofate companion diagnostic - Merrimack Pharmaceuticals

Drug Profile

Irinotecan sucrosofate companion diagnostic - Merrimack Pharmaceuticals

Alternative Names: Ferumoxytol - Merrimack Pharmaceuticals; MM-398 companion diagnostic

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merrimack Pharmaceuticals
  • Class Antianaemics; Contrast media; Diagnostic agents; Ferric compounds; Ferrous compounds; Heavy metals; Minerals
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Diagnosis) in USA (IV, Infusion)
  • 15 Mar 2016 Biomarkers information updated
  • 08 Apr 2014 Preliminary efficacy and adverse events data from a phase I pilot study released by Merrimack Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top